title: NZB/NZW F1 mouse nephritis and immune response are not changed by treatment with a 15-lipoxygenase derivative.
abstract: 15-HETE is an arachidonic acid derivative issued from the 15 lipoxygenase pathway. This fatty acid possesses immunomodulatory capabilities since it was reported that it generates CD8 + suppressor T-cells either in vitro or ex vivo. The aim of the present report was to study if the suppressive capabilities of 15-HETE were able to influence the onset of the NZB/NZW Fl auto-immune disease. For that purpose we produced 15-HETE and injected the eicosanoid twice a week to NZB/WFI mice for 40 weeks. During the 15-HETE treatment of the animals it was observed an augmentation of the proliferative response of lectin-stimulated splenocytes (at weeks 20 and 30) then the thymidine uptake decreased (at week 40). In fact we observed that among 15-HETE treated mice the evolution of the nephropathy was not changed, the 'glomerular activity score' remained the same for the treated animals compared to controls. On the contrary antinuclear antibodies occurred earlier even if in some experiments the generation of CD8 + cells was demonstrated.
authors.affiliation: Department of Nephrology, Centre Hospitalier Universitaire Dupuytren, Limoges, France.
authors.forename: J C
authors.initials: JC
authors.lastname: Aldigier
authors.forename: J
authors.initials: J
authors.lastname: Cook
authors.forename: S
authors.initials: S
authors.lastname: Delebassée
authors.forename: F
authors.initials: F
authors.lastname: Guibert
authors.forename: G
authors.initials: G
authors.lastname: Touchard
authors.forename: M
authors.initials: M
authors.lastname: Juzan
authors.forename: N
authors.initials: N
authors.lastname: Gualde
mesh_terms: D000818:Animals; D001323:Autoantibodies / Q000096:biosynthesis; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D005260:Female; D006893:Hydroxyeicosatetraenoic Acids / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C / Q000378:metabolism; D008814:Mice, Inbred NZB / Q000276:immunology; D012737:Sex Factors; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology
chemical_list: D001323:Autoantibodies; D006893:Hydroxyeicosatetraenoic Acids; C025984:15-hydroxy-5,8,11,13-eicosatetraenoic acid